Ovarian Cancer Update
About LCU CME Meetings Patterns of Care Patient Projects
You are here: Home: Audio Program Guide: OCU 3 | 2008 Audio: OCU 3 | 2008
 
 
  Go to interview with Tate Thigpen, MD
Go to interview with Ursula A Matulonis, MD
Go to interview with Robert A Burger, MD
Go to interview with Bradley J Monk, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Tate Thigpen, MD
Professor of Medicine
Director of Medical Oncology
University of MS Medical Center
Jackson, Mississippi

 
  Click here to download the entire interview  
Track 1 Conventional paclitaxel/carboplatin versus dose-dense weekly paclitaxel and carboplatin in advanced epithelial ovarian cancer, fallopian tube cancer (FTC) or primary peritoneal cancer (PPC)
Track 2 GOG-0126Q: A Phase II evaluation of pemetrexed in recurrent or persistent platinum-resistant ovarian cancer or PPC
Track 3 Perspective on the NCI clinical alert regarding intraperitoneal therapy for small-volume residual advanced ovarian cancer
Track 4 Proposed GOG trial comparing intravenous to intraperitoneal therapy
Track 5 Ongoing GOG studies evaluating maintenance therapy in advanced ovarian cancer
Track 6 Efficacy of bevacizumab during earlier-line therapy for advanced ovarian cancer

Track 7 Studies evaluating bevacizumab in combination with chemotherapy for patients with ovarian cancer
Track 8 Randomized studies of doublet chemotherapy versus single-agent platinums in platinum-sensitive, recurrent ovarian cancer
Track 9 Treatment algorithm for patients with platinum-resistant advanced ovarian cancer
Track 10 Tolerability and side effects of agents commonly used for platinum-resistant advanced ovarian cancer
Track 11 Clinical investigations of novel agents in ovarian cancer — pertuzumab, enzastaurin and patupilone
Track 12 Increasing therapeutic options for recurrent ovarian cancer
     
Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
  Click here to download the entire interview  
Track 1 GOG-0218: Carboplatin/paclitaxel with or without concurrent bevacizumab, with or without extended bevacizumab as up-front therapy for Stage III/IV epithelial ovarian cancer, PPC or FTC
Track 2 Rationale for maintenance bevacizumab/erlotinib in optimally debulked ovarian cancer
Track 3 Bevacizumab-associated bowel perforation in newly diagnosed versus recurrent ovarian cancer
Track 4 Clinical activity of bevacizumab in chemotherapy-refractory, recurrent ovarian cancer
Track 5 Bevacizumab and the palliation of symptomatic ascites in refractory ovarian cancer
Track 6 Clinical use of bevacizumab for recurrent ovarian cancer
Track 7 Bevacizumab-associated hypertension

Track 8 Pan-VEGFR tyrosine kinase inhibitor cediranib in recurrent epithelial ovarian cancer
Track 9 Identifying predictors of response to pertuzumab, a monoclonal antibody targeting the extracellular dimerization domain of the HER2 tyrosine kinase receptor
Track 10 Intraperitoneal administration of chemotherapy in optimally debulked Stage III ovarian cancer
Track 11 Therapeutic algorithm for patients with recurrent ovarian cancer
Track 12 Gemcitabine/carboplatin in platinum-sensitive, recurrent ovarian cancer
Track 13 Hypersensitivity reactions to carboplatin or paclitaxel
Track 14 Treatment options for patients with platinum-resistant ovarian cancer
audio
Track 15 Potential role for poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer
Track 16 Circulating tumor cells in ovarian cancer
Track 17 Treatment approach for asymptomatic patients with rising CA125 concentrations on follow-up for ovarian cancer
audio
Track 18 Clinical applications of hormonal therapy in ovarian cancer
     
Robert A Burger, MD
Associate Professor of Clinical Obstetrics and
Gynecology, Step II
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine Medical Center
Orange, California

 
  Click here to download the entire interview  
Track 1 GOG-0170D: A Phase II study of bevacizumab in persistent or recurrent epithelial ovarian cancer or PPC
Track 2 Early clinical experience with bevacizumab in ovarian cancer
Track 3 VEGF expression in ovarian cancer
Track 4 Activity of single-agent bevacizumab in recurrent ovarian cancer
Track 5 Gastrointestinal perforation events in Phase II trials of bevacizumab
Track 6 Historical cohort studies of bevacizumab in heavily pretreated patients with ovarian cancer

Track 7 Clinical use of single-agent bevacizumab in advanced ovarian cancer
Track 8 Continuation of bevacizumab after disease progression
Track 9 Caveats in the use of CA125 for monitoring disease progression in patients treated with anti-VEGF therapy
Track 10 Clinical algorithm for second- and later-line therapy in ovarian cancer
Track 11 Proposed Phase III trial of intraperitoneal chemotherapy in combination with bevacizumab for optimally debulked Stage III ovarian cancer
Track 12 Anticipated efficacy of adjuvant bevacizumab in ovarian cancer

     
Bradley J Monk, MD
Associate Professor and Director of Research
Division of Gynecologic Oncology
Chao Family Comprehensive Cancer Center
University of California, Irvine Medical Center
Orange, California

 
  Click here to download the entire interview
  
Track 1 Primary treatment for patients with ovarian cancer
Track 2 Standard therapy and controversies in the up-front treatment of epithelial ovarian cancer
Track 3 Perspective on intraperitoneal cisplatin/paclitaxel
Track 4 Current priority clinical trials in ovarian cancer: GOG-0218 (up-front chemotherapy/bevacizumab) and
GOG-0212 (consolidation therapy)
Track 5 Considerations for the clinical use of up-front chemotherapy with bevacizumab
Track 6 Rationale for the effectiveness of anti-VEGF therapy in ovarian cancer

Track 7 Clinical approach to patients with recurrent ovarian cancer
Track 8 Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed recurrent ovarian cancer
Track 9 Viewpoint on modest improvements in primary efficacy endpoints of clinical trials
Track 10 Phase III study of patupilone versus PLD for taxane- or platinum-refractory/resistant recurrent epithelial ovarian cancer, PFC or PPC
Track 11 Randomized Phase II study of gemcitabine with or without pertuzumab in ovarian cancer
Track 12 HER pathway gene expression analysis and prediction of benefit from pertuzumab
Track 13 Timing of initiation and discontinuation of treatment for recurrent ovarian cancer
Track 14 Bevacizumab-associated side effects during treatment of recurrent ovarian cancer